$20m-$39.9m

Lundbeckfonden Ventures took a board seat at Leiden spinout VarmX as part of a round that will fund development of a treatment for spontaneous bleeding.

Sodium-ion battery producer Natron, a Stanford spinout, has picked up corporates ABB and Chevron in a round bringing its lifetime funding to more than $70m.

University of Zurich-founded skin graft therapy developer Cutiss increased its funding total to $29.3m with a round featuring Wyss Foundation.

Wuxi AppTec and Pfizer have both contributed as the Yale University-founded cancer drug developer prepares for clinical testing next year.

Chinese Academy of Sciences-backed laser-diode chip foundry Everbright Photonics has now raised $63.3m since it was founded in 2012.

Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.

Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.